High-grade serous ovarian cancer development and anti-PD-1 resistance is driven by IRE1α activity in neutrophils

Related articles

1. Tumor Cells Enriched for Interferon and Inflammatory Programs Pre-Exist in High Grade Serous Ovarian Cancer and are Proportionately Significantly Increased Post Chemotherapy

   This article has 23 authors:

   1. Boris J.N. Winterhoff
   2. Nomeda Girnius
   3. Muyi Liu
   4. Jaeyoung Kang
   5. Mihir Shetty
   6. M. Angie Martinez-Gakidis
   7. Weiyi Xu
   8. Mayura Thomas
   9. Linna Lahmadi
   10. Aylin Z. Henstridge
   11. Pilar Baldominos
   12. Shobhana Talukdaer
   13. Zenas Chang
   14. Jordan Mattson
   15. Morgan Gruner
   16. Sally A. Mullany
   17. Peter Argenta
   18. Gottfried E. Konecny
   19. Dennis J. Slamon
   20. Ronny Drapkin
   21. Andrew C. Nelson
   22. Timothy K. Starr
   23. Joan S. Brugge

2. Sensitizing Immune-Refractory Ovarian Tumors via p53 Mutation-Tailored Immunotherapy

   This article has 27 authors:

   1. Rishita Chatterjee
   2. Arturo Simoni-Nieves
   3. An Truong
   4. Moshit Lindzen
   5. Furkan Ozmen
   6. Christopher Cherry
   7. Pascale Zwicky
   8. Saptaparna Mukherjee
   9. Boobash-Raj Selvadurai
   10. Tomer-Meir Salame
   11. Nitin Gupta
   12. Suvendu Giri
   13. Lior Kramarski
   14. Yahel Avraham
   15. Eviatar Weizman
   16. Tugba Ozmen
   17. Ashish Noronha
   18. Priyasmita Chakrabarti
   19. Deepthi Ramesh-Kumar
   20. Julian Downward
   21. Rony Dahan
   22. Ido Amit
   23. Victor Velculescu
   24. James Brenton
   25. Gordon Mills
   26. Moshe Oren
   27. Yosef Yarden

3. CD40 agonism enhances immune checkpoint blockade and generates immunologic memory via CD4+ T cells in ERα+ mammary tumors

   This article has 10 authors:

   1. Casey Lam
   2. Olivia Lanchoney
   3. Vishnu Maddipatla
   4. Nune Markosyan
   5. Nikhil Joshi
   6. Courtney Ray Fofana
   7. Shan Zeng
   8. Ronald P. DeMatteo
   9. Robert H. Vonderheide
   10. Jennifer Q. Zhang